Prestige Consumer Healthcare Inc.
PBH$3.09B
Mid CapNASDAQBiotechnology🇺🇸North America600 employees
Drugs in Pipeline
3
Phase 3 Programs
2
Upcoming Catalysts
1
Next Catalyst
Feb 15, 2026
7dData is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply
Market Overview
Stock performance and market intelligence
Catalyst Timeline
1 upcoming, 1 past
Phase 2Next
PBP1510 (400mg/16mL) Phase 2 Results Expected
February 2026~PBP1510 (400mg/16mL)80
Primary completion for PBP1510 (400mg/16mL) trial (NCT05141149) in Pancreatic Cancer
SourceAI Predictions & Institutional Flow
Machine learning insights and smart money movement
FDA Submissions
Pending NDA/BLA submissions with predicted PDUFA dates
Drug Pipeline
Clinical development programs and drug candidates
Drug Pipeline
HD204
Lung Cancer
HD201
HER2 Positive Breast Cancer
PBP1510 (400mg/16mL)
Pancreatic Cancer
| Drug Name | Phase | Indication | Designations |
|---|---|---|---|
HD204 | Phase 3 | Lung Cancer | - |
HD201 | Phase 3 | HER2 Positive Breast Cancer | - |
PBP1510 (400mg/16mL) | Phase 2 | Pancreatic Cancer | - |
Regulatory & News
Approvals, filings, and latest developments
Regulatory Approvals
PBH News